HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Chatterjee, A. Articles by Srinivas, N. R. Search for Related Content PubMed PubMed Citation Articles by Chatterjee, A. Articles by Srinivas, N. R.

Safety, Tolerability, and Pharmacokinetics of a Capsule Formulation of DRF-1042, a Novel Camptothecin Analog, in Refractory Cancer Patients in a Bridging Phase I Study

From Dr. Reddy's Laboratories Ltd, Hyderabad, India (A. Chatterjee, K. Katneni, V. Upreti, Dr Mamidi, Dr Mullangi, Dr N. R. Srinivas) and Nizam's Institute of Medical Sciences, Hyderabad, India (Dr Digumarti, A. Surath, Dr M. L. Srinivas, S. Uppalapati, S. Jiwatani).

The purpose of this bridging phase I study was to characterize the toxicity, pharmacokinetics, and antitumor effects of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory solid tumor patients. DRF-1042 was given daily for 5 consecutive days for 2 weeks, repeated every 3 weeks at 81 mg/m². Adverse events were monitored following NCI-CTC. Blood samples were processed for bioanalysis using a validated high-performance liquid chromatography method. The pharmacokinetics of lactone and total (lactone + carboxylate) forms was determined on days 1 and 12 using a noncompartmental pharmacokinetic method. Pharmacokinetic data with the capsule formulation were compared with previously reported pharmacokinetic parameters with a suspension formulation. Efficacy was evaluated by applying World Health Organization criteria. Six patients received 10 courses of therapy. Thrombocytopenia and diarrhea were dose-limiting toxicities. The upper limit of the area under the curve of DRF-1042 (lactone and total) with the capsule formulation was higher than a suspension formulation at a similar dose on day 1 (lactone: capsule = 8.53 µM•h, suspension = 5.33 µM•h; total: capsule = 393 µM•h, suspension = 176 µM•h) and day 12 (lactone: capsule = 22.1 µM•h, suspension = 6.1 µM•h; total: capsule = 1302 µM•h, suspension = 309 µM•h). The upper limit of the area under the curve of DRF-1042 (lactone and total) was higher under fed conditions (lactone = 15.9 µM•h, total = 605 µM•h) relative to fasted conditions (lactone = 8.53 µM•h, total = 393 µM•h) on day 1. One patient experienced stable disease. The toxicity and pharmacokinetics of the capsule correlated well with the suspension. The recommended phase II dose is 81 mg/m².

Key Words: DRF-1042 • camptothecin • pharmacokinetics • toxicity • cancer • topoisomerase I inhibitors

Address for reprints: Nuggehally R. Srinivas, PhD, FCP, Dr. Reddy's Laboratories, Discovery Research, Bollaram Road, Miyapur, Hyderabad—500 049, India.